SILO Pharma Inc SILO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $7.73
- Day Range
- $5.37–6.30
- 52-Week Range
- $3.32–15.15
- Bid/Ask
- $5.65 / $5.70
- Shares Outstanding
- 1.13M
- Market Cap
- $6.43M
- Volume/Avg
- 379,628 / 195,605
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 55.94
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 3
- Website
- https://www.silopharma.com
Valuation
|
Metric
|
SILO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.08 |
Price/Sales | 55.94 |
Price/Cash Flow | — |
Price/Earnings
SILO
Financial Strength
|
Metric
|
SILO
|
|---|---|
Quick Ratio | 8.90 |
Current Ratio | 9.65 |
Interest Coverage | −128.87 |
Quick Ratio
SILO
Profitability
|
Metric
|
SILO
|
|---|---|
Return on Assets (Normalized) | −68.55% |
Return on Equity (Normalized) | −88.74% |
Return on Invested Capital (Normalized) | −91.29% |
Return on Assets
SILO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#dP&bWf | LOCK|CLxt | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|hdT@>JR | LOCK|?%!< | $70B | |||
| argenx SE ADR
ARGX
| LOCK|$T&?db | LOCK|?^@ | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|qpNkm< | LOCK|@S#rX | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|!Zpw?%F | LOCK|SX | $36B | |||
| Moderna Inc
MRNA
| LOCK|GJ@w!^ | LOCK|jk | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|LJkf$&dF | LOCK|w@##? | $25B | |||
| Incyte Corp
INCY
| LOCK|><?WdH | LOCK|yw@ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Wn$D##Y | LOCK|%JN | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|BC?Kc^ | LOCK|<t@ | $17B |
United States